Search results
Results from the WOW.Com Content Network
Cariprazine is used to treat patients with schizophrenia and manic, depressive, or mixed episodes associated with bipolar I disorder.In the United States it is approved for schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and treatment of depressive episodes associated with bipolar I disorder (bipolar depression).
Tiotixene is a widely used drug for the treatment of various psychiatric disorders such as schizophrenia, bipolar disorder, mania, and behavioural disturbances. [7] The drug regulates behaviour and thoughts, and can also exhibit an anti-depressive effect.
At least five atypical antipsychotics (lumateperone, [48] cariprazine, [49] lurasidone, [50] olanzapine, [51] and quetiapine [52]) have also been found to possess efficacy in the treatment of bipolar depression as a monotherapy, whereas only olanzapine [53] and quetiapine [54] [55] have been proven to be effective broad-spectrum (i.e., against ...
In a meta-analysis of 18 antipsychotics, olanzapine and clozapine exhibited the worst metabolic parameters and aripiprazole, brexpiprazole, cariprazine, lurasidone, and ziprasidone the most benign parameters. [70] Aripiprazole, asenapine, ziprasidone and lurasidone have low propensity to cause weight gain. [71]
In another language, the Wikipedia article on Cariprazine states that weight gain may be a common side effect. If this is correct, it should be added to the English article also, ideally quantified or compared to other second-gen antipsychotics. Note, there is document [1], page 12 (in German), which seems to provide some numbers.
English: Chemical structure of cariprazine (brand name Vraylar) — an atypical antipsychotic used in the treatment of schizophrenia and bipolar disorder. Date 28 October 2011, 16:51 (UTC)
The percentage of patients who gained weight during the trial was 2.1% for brilaroxazine 15 mg, 5.9% for 50 mg, and 2.9% for placebo. This is a significant improvement over the currently prescribed third-generation antipsychotics aripiprazole (Abilify), brexpiprazole (Rexulti), and cariprazine (Vraylar). In comparable short-term (4-6 week ...
Iloperidone is indicated for the treatment of schizophrenia and mania or mixed episodes in bipolar I disorder. [2] [3] In a 2013 study in a comparison of 15 antipsychotic drugs in effectivity in treating schizophrenic symptoms, iloperidone demonstrated mild effectiveness -- as effective as lurasidone, and 13 to 15% less effective than ziprasidone, chlorpromazine, and asenapine. [4]